Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
An exploratory phase 1/2 trial to determine recommended phase 2 dose (RP2D), safety and preliminary efficacy of bb2121 (ide-cel) combinations in subjects with refractory/relapsed multiple myeloma (KarMMa-7)

Proposed period of release:
01/01/2021 to 30/03/2023

Name of the Institute(s) or Company(ies)
Celgene Corporation, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):
B/DE/17/PEI3269; B/DE/19/PEI3525; B/DE/19/PEI3673; B/ES/17/18; B/ES/18/26; B/ES/18/30; B/NL/19/005;

GMO characterization

GMO is a:
Other: mammals

Identity of the GMO:
The GMO, referred to as ide-cel (bb2121), is an autologous Homo Sapiens T lymphocyte population transduced with the anti-BCMA02 CAR lentiviral vector (LVV), which encodes a chimeric antigen receptor (CAR) targeting the human B cell maturation antigen (BCMA).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known